Kirstin Goldring, Principal Scientist at Astra Zeneca, Counselor at the European Society for Biopreservation and Biobanking, Member of ISBER
0:00 The sharers
5:25 What is the HTA and would it work here in the US?
12:56 What have you heard back from the public regarding the consent process?
18:24 Are we getting better at sample quality?
For the next episode in our summer series on human tissue sample quality and biobanking, we turn to a veteran biobanker in the U.K. who managed several projects there including the U.K. Parkisons’ Disease Society Brain Bank at Imperial College.
Today we talk to Kirstin Goldring, Principal Scientist at Astra Zeneca where she’s in charge of Human Biological Sample Strategy and Governance. Kirstin is a counselor at the European Society for Biopreservation and Biobanking and also a member of ISBER or the International Society for Biorepositories.
So far, in the U.S. biobanks are not regulated. In the U.K., they have what is called the Human Tissue Authority or HTA. Kirstin explains that the HTA is really some light governance that leaves a lot open to the biobanks as to how they go about maintaining standards. Could the program be a model for us here in the U.S.?
What has been Kirstin's overall take away on the field after managing different projects in various locations? Are we getting any better at sample quality?